- Open
- 510.00
- High
- 518.00
- Low
- 507.00
- Close
- 516.00
- Change
- +2.00 (0.39%)
- Volume
- 83,074
| 9 Oct 2026 | 09:11:26 | Admission to Trading |
| 6 Oct 2026 | 14:43:15 | PDMR Dealing |
| 6 Oct 2026 | 10:36:37 | Admission to Trading |
| 2 Oct 2026 | 14:41:50 | Grant of Award |
| 1 Oct 2026 | 07:00:01 | Total Voting Rights |
| 30 Mar 2026 | Annual financial and audit reports | |
| 28 Apr 2025 | Annual financial and audit reports | |
| 30 Apr 2024 | Annual Report and accounts 31-Dec-2023 |
Oxford Biomedica plc operates as a contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. The company focuses on the development and manufacturing of viral vectors, including lentivirus and adeno-associated virus (AAV), for pharmaceutical and biotechnology clients. Its services span from early-stage development to commercial production, supported by quality assurance and regulatory expertise. Oxford Biomedica has facilities in the UK, France, and the US, serving a global market with a growing demand for advanced therapeutic solutions.
| 9 Oct 2026 | 09:11:26 | Admission to Trading |
| 6 Oct 2026 | 14:43:15 | PDMR Dealing |
| 6 Oct 2026 | 10:36:37 | Admission to Trading |
| 2 Oct 2026 | 14:41:50 | Grant of Award |
| 1 Oct 2026 | 07:00:01 | Total Voting Rights |
| 30 Mar 2026 | Annual financial and audit reports | |
| 28 Apr 2025 | Annual financial and audit reports | |
| 30 Apr 2024 | Annual Report and accounts 31-Dec-2023 |
Oxford Biomedica plc operates as a contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. The company focuses on the development and manufacturing of viral vectors, including lentivirus and adeno-associated virus (AAV), for pharmaceutical and biotechnology clients. Its services span from early-stage development to commercial production, supported by quality assurance and regulatory expertise. Oxford Biomedica has facilities in the UK, France, and the US, serving a global market with a growing demand for advanced therapeutic solutions.
| Issuer | Mkt cap | 1Y |
|---|---|---|
OXBOxford Biomedica plc | £625m | -0.2% |
| £619m | +0.2% | |
| £11m | -0.1% | |
| £11m | +0.0% | |
| £3m | -0.9% | |
| £377k | -0.8% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
OXBOxford Biomedica plc | £625m | -0.2% |
| £619m | +0.2% | |
| £11m | -0.1% | |
| £11m | +0.0% | |
| £3m | -0.9% | |
| £377k | -0.8% |